Mirador unveils part of pipeline with drug from Kira to rival Tavneos

PartnershipPositive

AI Analysis

Summary

Mirador Therapeutics, a well-funded San Diego biotech, announced a deal to acquire worldwide rights to a drug from Kira to compete in the immune disease market, revealing part of its previously undisclosed pipeline.

Outcome Details

Mirador Therapeutics reached a deal for worldwide rights to a drug from Kira

Importance:6/10

Sentiment:

0.30

partnershipdrug_licensingpipeline_expansionimmune_diseaseventure_funding

Read the original article

Published by Endpoints News on July 16, 2026 9:47 PM

Read Original